Zentalis Pharmaceuticals (ZNTL) EBT (2019 - 2026)

Zentalis Pharmaceuticals' EBT history runs 8 years deep, the most recent figure standing at -$35.2 million for Q1 2026.

• In Q1 2026, EBT rose 27.02% year-over-year to -$35.2 million; the TTM figure through Mar 2026 stood at -$123.6 million (up 44.87% YoY), while the FY2025 annual figure was -$136.6 million, up 17.55% from the prior year.
• EBT for Q1 2026 stood at -$35.2 million, down from -$34.8 million in the prior quarter.
• The five-year high for EBT was $10.2 million in Q1 2024, with the low at -$99.5 million in Q2 2023.
• The 5-year median for EBT is -$48.5 million (2022), against an average of -$49.2 million.
• The sharpest annual moves came in 2024 and 2025: EBT surged 116.74% in 2024, then sank 574.11% in 2025.
• Zentalis Pharmaceuticals' EBT stood at -$48.5 million in 2022, then declined by 25.87% to -$61.1 million in 2023, then climbed by 21.94% to -$47.7 million in 2024, then gained by 27.06% to -$34.8 million in 2025, then dropped by 1.32% to -$35.2 million in 2026.
• Business Quant data shows ZNTL's EBT at -$35.2 million in Q1 2026, -$34.8 million in Q4 2025, and -$26.7 million in Q3 2025.